Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.43 |
| ▸ | CA2 | P00918 | 13/20 | 0.43 |
| ▸ | CA12 | O43570 | 9/20 | 0.43 |
| ▸ | CA7 | P43166 | 9/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 7/20 | 0.43 |
| ▸ | CA9 | Q16790 | 6/20 | 0.38 |
| ▸ | CA6 | P23280 | 3/20 | 0.38 |
| ▸ | CA5A | P35218 | 3/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24812540 | 0.85 | KDM4E (0.41) | CA1CA2CA12CA7CA13 | |
| SCHEMBL28438608 | 0.83 | CA2 (0.37) | CA1CA2CA12CA7CA13 | |
| SCHEMBL20000082 | 0.79 | KDM4E (0.46) | CA1CA2CA12CA7CA13 | |
| SCHEMBL111253 | 0.79 | CA1 (0.35) | CA1CA2CA12CA7CA13 | |
| SCHEMBL10204147 | 0.77 | CA12 (0.38) | CA1CA2CA12CA7CA13 | |
| SCHEMBL2933802 | 0.77 | RAB9A (0.47) | CA1CA2CA12CA7CA13 | |
| SCHEMBL28857875 | 0.74 | RAPGEF4 (0.41) | CA1CA2CA12CA7CA13 | |
| SCHEMBL10204142 | 0.73 | CA12 (0.35) | CA1CA2CA12CA7CA13 | |
| SCHEMBL2932203 | 0.73 | RAB9A (0.53) | CA1CA2CA12CA7CA13 | |
| SCHEMBL14001796 | 0.72 | GAA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885693-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | Wurster, Siegfried (FI) | 2008-02-13 | — | — | EP | claimed |
| WO-2006123020-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | JUVANTIA PHARMA LTD OY (FI) | 2006-11-23 | — | — | WO | claimed |
| EP-0694041-A1 | A PROCESS AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS CONTAINING N-ALPHA-METHYLARGININE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-31 | — | — | EP | claimed |
| WO-1994022911-A2 | A PROCESS AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS CONTAINING Nα-METHYLARGININE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | claimed |
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| WO-2025077996-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025050647-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 晟迪生物医药(苏州)有限公司 | 2025-03-13 | — | — | WO | disclosed |
| WO-2025050066-A1 | COMPOSITIONS INCLUDING SMALL-MOLECULE TERT ACTIVATOR COMPOUNDS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-06 | — | — | WO | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| CN-110621678-B | Antitumor compounds | 法马马有限公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2010149688-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-12-29 | — | — | WO | disclosed |
| US-20100292163-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-18 | — | — | US | disclosed |
| EP-2231695-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009077401-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-06-25 | — | — | WO | disclosed |
| EP-1885693-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | Wurster, Siegfried (FI) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006123020-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | JUVANTIA PHARMA LTD OY (FI) | 2006-11-23 | — | — | WO | disclosed |
| EP-0694041-A1 | A PROCESS AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS CONTAINING N-ALPHA-METHYLARGININE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-31 | — | — | EP | disclosed |
| WO-1994022911-A2 | A PROCESS AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS CONTAINING Nα-METHYLARGININE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384800-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | CA1 567/4885CA2 2447/4885CA12 277/4885 |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | MCL1, XPOT, GZMB | CA1 945/4885CA2 2208/4885CA12 305/4885 |
| US-20100292163-A1 | Antitumoral Compounds | TP53, XPO1, TOP2B | CA1 305/4885CA2 1486/4885CA12 155/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | CA1 3319/4885CA2 3243/4885CA12 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.